Text Size

Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients (VITALITE)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01007734
First received: October 31, 2009
Last updated: July 26, 2010
Last verified: July 2010
History of Changes
  Purpose

The purpose of this study is to evaluate with sufficient precision and according to gender the determining independent factors of quality of life related to respiratory status of patient with moderate to severe COPD.


Condition
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Factors Determining Quality of Life Related to Respiratory Status According to Gender of COPD Patients Followed by a Pneumologist

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate with sufficient precision and according to gender the determining independent factors of quality of life related to respiratory status of patient with moderate to severe COPD [ Designated as safety issue: No ]

Enrollment: 449
Study Start Date: October 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First 3 consecutive adults with COPD with at least a three month follow up, seen by pneumologist

Criteria

Inclusion Criteria:

  • Adult patient who has a clinical visit for their usual follow-up.
  • patient with COPD with at least a three month follow up

Exclusion Criteria:

  • Current or history of asthma
  • Current participation in an interventional clinical study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01007734

  Show 185 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Alain Castaigne, Medical Director AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01007734     History of Changes
Other Study ID Numbers: NIS-RFR-DUM-2009/1
Study First Received: October 31, 2009
Last Updated: July 26, 2010
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Quality of life
COPD patients
Evaluation According to Gender the Determining Independent Factors of Quality of Life Related to Respiratory Status of Patient With Moderate to Severe COPD

Additional relevant MeSH terms:
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 16, 2013